http://localhost:8080/xmlui/handle/123456789/8912 Sat, 18 Apr 2026 17:13:24 GMT 2026-04-18T17:13:24Z http://localhost:8080/xmlui/handle/123456789/9058 Title: Current Updates on Diagnosis and Management of Cholangiocarcinoma: from Surgery to Targeted Therapy Authors: Surya, Haryanto; Abdullah, Murdani; Juwita Nelwan, Erni; Syam, Ari F.; Bima Prasetya, Ignatius; Stefanus, Benedictus Abstract: ABSTRACT Cholangiocarcinoma is commonly described as any malignancy arising from the lining of the bile duct and is recognized as one of the most common biliary malignancies. We conducted a literature review of current available evidences and guidelines. Based on the anatomical location of the origin of the mass, cholangiocarcinoma can be divided into intrahepatic, perihilar, and distal cholangiocarcinoma. Each of these subtypes has their own risk factors, best treatment options, and prognosis. The most common risk factors for cholangiocarcinoma also differs based on geography and population backgrounds. Histopathological biopsy remained the gold standard for cholangiocarcinoma diagnosis, however various advances has been made in diagnostic procedure, including MRCP, EUS, ERCP, EBUS, and cholangioscopy. Surgical resection is still the best treatment modality for cholangiocarcinoma, but it can only be done in few patients considering most patients were diagnosed in the unresectable state. Other treatment options includes conventional chemotherapy, locoregional therapy, systemic targeted therapy, and palliative best supportive care. Cholangiocarcinoma has an abundance of molecular targets and advances in biomolecular technologies bring further hope for future curative treatment options. Treatment options should be chosen individually based on each patient’s condition and setting. Cholangiocarcinoma is still a major health problem in hepatobiliary malignancies. Multiple options are available for cholangiocarcinoma treatments. Keywords. Cholangiocarcinoma, biliary malignancy, targeted therapy. Sat, 01 Jul 2023 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/9058 2023-07-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/9054 Title: Risk of Non-melanoma Skin Cancer in Kidney Transplantation Recipient: An Evidence-based Case Report Authors: Ambardina Pradita, Riva; Saraswati Adisasmito, Ayutika; Indriatmi, Wresti Abstract: ABSTRACT Background: Renal transplantation is the most common organ transplantation procedure in Indonesia. Renal transplant recipients (RTRs) were found to carry 3-to-5-time higher risk of cancer compared to the normal population. Around 40% of cancers in RTR patients were non-melanoma skin cancer (NMSC). It was found to be correlated with several risk factors. The study aimed to determine the prognostic factors for NMSC in RTRs with Indonesian skin colors. Methods: The article search was conducted on three different journal databases, which were Cochrane, PubMed, and Embase. Relevant articles were appraised using critical appraisal guidelines from The Centre for Evidence-Based Medicine (CEBM), University of Oxford. Results: Four articles were selected for appraisal. Incidence of NMSC on RTRs in these studies were 25,2% (CI 24,67%-32,47%), 6,67% (CI 2,87%- 10,47%), 23,67% (CI 19,38%-27,96%) and 28,57% (CI 24,67%-32,47%). Prognostic factors correlated with the incidence of NMSC on RTRs were age, sun exposure, history of sunburn, existing chronic actinic lesion, lentigo solaris, precancerous lesion including actinic keratoses, and consumption of cyclosporine and tacrolimus during maintenance therapy. Conclusion: Combination of age, environmental factors, sun exposure-related skin lesion, and immunosuppressant therapy are the main prognostic factors of NMSC on RTRs. Keywords: non-melanoma skin cancer, renal transplant recipient, renal transplantation Sat, 01 Jul 2023 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/9054 2023-07-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/9052 Title: A Rare Case of Prostatic Malakoplakia Associated with Prostate Adenocarcinoma: A Case Report and Review of Literature Authors: Rances, Orlando T.; So, Jeffrey S. Abstract: ABSTRACT Malakoplakia is a chronic granulomatous condition that has been rarely seen affecting the prostate. Isolated malakoplakia of the prostate occurring together with prostatic adenocarcinoma is rarer still with only 9 previously recorded cases. We present a case diagnosed through needle biopsy with prostatic adenocarcinoma and then on subsequent prostatectomy was diagnosed with extensive malakoplakia occurring with the carcinoma. Patient was noted to have a urinary tract infection (UTI) 2 weeks after needle biopsy and notably, 4 of the 9 previously reported cases also presented with UTI following their biopsies. The theory that prostatic malakoplakia may be a complication of the prostate needle biopsy is logically possible, but due to the paucity in cases, it is difficult to infer causality. Keywords: Prostatic malakoplakia, Adenocarcinoma Sat, 01 Jul 2023 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/9052 2023-07-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/9039 Title: COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review Authors: Harjianti, Tutik; Benyamin, Fachrudin; Minhajat, Rahmawati; Saleh, Sahyuddin; Bayu, Dimas; Pababbari, Wahyudi Abstract: ABSTRACT Management of chronic myeloid leukemia (CML) in patients who are infected with COVID-19 is a challenging task due to disease-related or treatment-related factors that place such patients at a higher risk of complications. However, a low-infectivity-rate mechanism has been proposed by some researchers. In CML patients with COVID-19 infection, the most important treatment-related factor involves tyrosine kinase inhibitors (TKIs). In this case report, six patients with chronic-phase CML who experienced COVID-19 of mild–moderate severity all continued to receive TKI treatment for CML concurrently with COVID-19 treatment. All patients fully recovered. In the present study, we also review four other cases of COVID-19 infection in CML patients. Outcomes for TKI-treated CML patients who contract COVID-19 are influenced by many factors. Tyrosine kinase inhibitor therapy may benefit CML patients due to its antiviral effect, but the interaction between TKIs and drugs used for COVID-19 treatment requires careful monitoring. An individual approach is needed in every case. Keywords : Chronic Myeloid Leukemia, Tyrosine Kinase Inhibitor, COVID-19, Case Report Sat, 01 Jul 2023 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/9039 2023-07-01T00:00:00Z